HK1035492A1 - Devices for providing prolonged drug therapy. - Google Patents

Devices for providing prolonged drug therapy.

Info

Publication number
HK1035492A1
HK1035492A1 HK01106150A HK01106150A HK1035492A1 HK 1035492 A1 HK1035492 A1 HK 1035492A1 HK 01106150 A HK01106150 A HK 01106150A HK 01106150 A HK01106150 A HK 01106150A HK 1035492 A1 HK1035492 A1 HK 1035492A1
Authority
HK
Hong Kong
Prior art keywords
devices
drug therapy
prolonged drug
providing prolonged
drug
Prior art date
Application number
HK01106150A
Other languages
English (en)
Inventor
Atul D Ayer
Carol A Christopher
Diane R Guinta
Suneel K Gupta
Lawrence G Hamel
Hatamkhany Zahedeh
Andrew C Lam
Samuel R Saks
Padmaja Shivanand
Richard G Weyers
Jeri D Wright
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/253,317 external-priority patent/US6919373B1/en
Application filed by Alza Corp filed Critical Alza Corp
Publication of HK1035492A1 publication Critical patent/HK1035492A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/88—Investigating the presence of flaws or contamination
    • G01N21/95—Investigating the presence of flaws or contamination characterised by the material or shape of the object to be examined
    • G01N21/9508—Capsules; Tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK01106150A 1998-06-03 2001-08-31 Devices for providing prolonged drug therapy. HK1035492A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8778798P 1998-06-03 1998-06-03
US09/253,317 US6919373B1 (en) 1996-11-12 1999-02-19 Methods and devices for providing prolonged drug therapy
PCT/US1999/011920 WO1999062496A1 (en) 1998-06-03 1999-05-27 Methods and devices for providing prolonged drug therapy

Publications (1)

Publication Number Publication Date
HK1035492A1 true HK1035492A1 (en) 2001-11-30

Family

ID=26777397

Family Applications (2)

Application Number Title Priority Date Filing Date
HK01106150A HK1035492A1 (en) 1998-06-03 2001-08-31 Devices for providing prolonged drug therapy.
HK02108159.8A HK1046638B (zh) 1998-06-03 2002-11-11 提供藥物長效治療的方法和裝置

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02108159.8A HK1046638B (zh) 1998-06-03 2002-11-11 提供藥物長效治療的方法和裝置

Country Status (16)

Country Link
EP (2) EP1449524A1 (de)
JP (1) JP2002516848A (de)
KR (1) KR20080083074A (de)
CN (1) CN1209098C (de)
AT (1) ATE277594T1 (de)
AU (1) AU4319799A (de)
CA (1) CA2333688A1 (de)
DE (1) DE69920689T2 (de)
DK (1) DK1083879T3 (de)
ES (1) ES2229783T3 (de)
HK (2) HK1035492A1 (de)
IL (1) IL140020A0 (de)
NO (1) NO330235B1 (de)
NZ (1) NZ508567A (de)
PT (1) PT1083879E (de)
WO (1) WO1999062496A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
JP4613275B2 (ja) 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
EP1248595A4 (de) * 2000-01-20 2006-06-14 Delsys Pharmaceutical Corp Darreichungsformen zur stufenweisen freisetzung von arzneistoffen
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20020187192A1 (en) * 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
US20030049272A1 (en) * 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US20040062804A1 (en) 2001-09-28 2004-04-01 Der-Yang Lee Modified release dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
ATE373472T1 (de) * 2002-07-29 2007-10-15 Alza Corp Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
NZ538842A (en) * 2002-09-28 2008-03-28 Mcneil Ppc Inc Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids
GR1004330B (el) * 2002-10-14 2003-09-05 Lavipharm A.E. Φαρμακοτεχνικη μορφη για τη χορηγηση οργανικων νιτρικων ενωσεων
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
WO2004071497A1 (en) * 2003-02-11 2004-08-26 Alza Corporation Methods and dosage forms with modified layer geometry
EP1708684A2 (de) 2003-09-26 2006-10-11 Alza Corporation Arzneimittelbeschichtung mit hoher arzneimittelbeladung und verfahren dafür
ES2373042T3 (es) 2003-10-08 2012-01-30 Mallinckrodt Llc Solución de metilfenidato y procedimientos de administración y producción asociados.
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CA2566310C (en) * 2004-05-21 2014-05-13 Lawrence Solomon Scored pharmaceutical tablets comprising a plurality of segments
ES2261006B1 (es) * 2004-06-10 2007-11-01 Laboratorios Rubio, S.A. Pellet multicapa de liberacion controlada de metilfenidato.
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2009023006A2 (en) * 2006-05-08 2009-02-19 Mcneil-Ppc, Inc. Modified release dosage form
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
FR2899476B1 (fr) * 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
CA2742680C (en) 2008-11-07 2013-12-31 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
AU2010328353B2 (en) 2009-12-07 2015-07-16 Mcneil-Ppc, Inc. Partial dip coating of dosage forms for modified release
UY34856A (es) * 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida
WO2014174388A1 (en) * 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of methylphenidate or salts thereof
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN113891713A (zh) 2019-01-25 2022-01-04 艾伦索尔医药发展股份有限公司 用于治疗注意力缺陷多动障碍的哌甲酯组合物
CA3130379A1 (en) * 2019-03-05 2020-09-10 Kashiv Biosciences, Llc Delayed release methylphenidate compositions
CN114681422B (zh) * 2020-12-30 2023-09-05 深圳翰宇药业股份有限公司 一种硝苯地平控释片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
CN1096862C (zh) * 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
ATE234602T1 (de) * 1996-08-16 2003-04-15 Alza Corp Verabreichungsform zur abgabe von steigenden wirkstoffdosen
ES2262174T3 (es) * 1996-09-30 2006-11-16 Alza Corporation Forma de dosificacion y procedimiento de administracion de medicamentos.

Also Published As

Publication number Publication date
DE69920689D1 (de) 2004-11-04
EP1449524A1 (de) 2004-08-25
NO20006007L (no) 2001-02-05
CN1209098C (zh) 2005-07-06
JP2002516848A (ja) 2002-06-11
PT1083879E (pt) 2005-01-31
DK1083879T3 (da) 2005-01-31
WO1999062496A1 (en) 1999-12-09
NZ508567A (en) 2004-02-27
DE69920689T2 (de) 2005-02-24
CN1352549A (zh) 2002-06-05
ATE277594T1 (de) 2004-10-15
IL140020A0 (en) 2002-02-10
HK1046638B (zh) 2006-02-24
EP1083879B1 (de) 2004-09-29
ES2229783T3 (es) 2005-04-16
KR20080083074A (ko) 2008-09-12
EP1083879A1 (de) 2001-03-21
HK1046638A1 (en) 2003-01-24
AU4319799A (en) 1999-12-20
CA2333688A1 (en) 1999-12-09
NO330235B1 (no) 2011-03-07
NO20006007D0 (no) 2000-11-28

Similar Documents

Publication Publication Date Title
HK1035492A1 (en) Devices for providing prolonged drug therapy.
HK1077501A1 (en) Improved delivery of multiple doses of a methylphenidate drug
MXPA03003895A (es) Formulaciones de hidrocodona de liberacion controlada.
EP1566174A3 (de) In der Mundhöhle schnell zerfallende orale feste Verabreichungsform
IL209703A0 (en) Controlled release hydrocodone formulations
EP1514105A4 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
EP0699072A4 (de) Eisenbindende polymere zur oralen verabreichung
EP1091732A4 (de) Arzneistoffverabreichungssystem mit brauseaktivität zur oralen verabreichung
IL120382A (en) Extended release formulation of venlafaxine hydrochloride
HK1043048A1 (en) Combinations of formoterol and mometasone furoate
BG104620A (en) Oral pharmaceutical extended release dosage form
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
EP1207852A4 (de) Orale darreichung mit gesteuerter freisetzung zur oralen verabreichung
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
EP1578464A4 (de) Therapeutisches einzeldosengasverabreichungssystem
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
PL325509A1 (en) Therapeutic agent for oral administration
NO971574D0 (no) Medisinmateanordning for tildeling av medisin via munnen særlig beregnet for mindre barn
UA32029A (uk) Лікарська плівка для терапії захворювань пародонту і слизової оболонки ротової порожнини
IL160195A0 (en) Oral dosage form comprising a therapeutic agent and an adverse-effect agent
GB9905720D0 (en) Medicine dose monitor

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190526